G382

PDF page 473 / J59

Management of special oral chemotherapy
          This is the service for the supervision of oral chemotherapy treatment for malignant disease
          where the agent(s) has a significant risk of toxicity in the period immediately following initiation.
          The physician must be available to intervene in a timely fashion for a 24 hour period following
          the initiation of the treatment.
          In addition to the Common Elements in this Schedule, this service includes the provision of the
          following services to the same patient:
         a. evaluation of any relevant laboratory, diagnostic and/or imaging investigations; and
         b. all discussion or advice, whether by telephone or otherwise, involving the patient, staff,
            patient’s relative(s) or patient’s representative related to the oral chemotharapy for a period
            of twenty-one (21) days following initiation of the agent(s).
   G388 Management of special oral chemotherapy, for malignant
          disease ...............................................................................   28.00
          Payment rules:
          1. G388 is not eligible for payment for the same patient in the same month where G382 is
            payable.
          2. G388 is only eligible for payment once per patient per month
          [Commentary:
          Examples of special oral chemotherapy include fludarabine, imatinib, dasatanib, nilotinib,
          erlotinib, capecitabine, sunitinib, sorafenib, thalidomide, temazolamide and lenalidomide.]

Master, record 2094. Record Layout PDF, page 1.

G38220250401999999990000013950000000000000000000000000000000000000000000000

Auxiliary master fields are preserved as raw scaled values. The linked layout calls them zero-filled, but this edition contains non-zero values. They are not presented as final dollar fees or PDF units.